<DOC>
	<DOCNO>NCT02007941</DOCNO>
	<brief_summary>The purpose study assess renal impaired patient normal renal function subject comparetive evaluation Pharmacokinetics CKD-501 Future , When prescription CKD-501 renal impaired patient , It guideline provide basis instruction .</brief_summary>
	<brief_title>Comparative Evaluation Pharmacokinetics After CKD-501 Between Renal Impaired Normal Renal Function Subjects</brief_title>
	<detailed_description>A Phase 1 , Non-randomized , Open , Parallel-Group Clinical trial</detailed_description>
	<mesh_term>Renal Insufficiency</mesh_term>
	<criteria>Inclusion Criteria All subject : Adult male female , 20 65 year age ( inclusive ) ; Body mass index ( BMI ) range approximately 18.529.9 kg/㎡ ( inclusive ) ; Agreement write informed consent Agree Medically acceptable method contraception clinical trial Normal Renal Function subject : Matched renal impaired patient ( ESRD ) study age ( ±7 year ) , sex BMI Medically healthy clinically insignificant screen result ( e.g. , laboratory profile , medical history , EKG , physical examination ) ; eGFR ≥ 90 mL/min/1.73mE2 ; Renally impaired subject : Matched renal impaired patient ( ESRD ) study age ( ±7 year ) , sex BMI Subjects mild renal impairment ( eGFR 6089 mL/min/1.73mE2 ) OR moderate renal impairment ( eGFR 3059 mL/min/1.73mE2 ) OR severe renal impairment ( eGFR 1529 mL/min/1.73mE2 ) OR dialysis end stage renal disease ( ESRD ) Exclusion Criteria All subject : The subject 's systolic blood pressure outside range 100180mmHg , diastolic blood pressure outside range 50110mmHg Repeatedly Screening ECG parameter ( PR ≥ 210 mse , QRS ≥ 120 msec , QTcF ≥ 500 msec ) Repeatedly lab ( AST &gt; 1.25xULN , ALT &gt; 1.25xULN , Total bilirubin &gt; 1.5xULN ) A positive prestudy drug screen . ( amphetamine , barbiturate , cocaine , opiates , cannabinoids , benzodiazepin ) Clinically significant allergic disease History thiazolidinedione class 's anaphylaxis reaction Can stop take caffeine ( caffeine &gt; 400mg/day ) , drink ( alcohol &gt; 30 g/day ) severe heavy smoker ( cigarette &gt; 10 cigarettes/day ) clinical trial Consumption food may affect study within 7 day prior first dose study medication take dietary supplement continue . Consumption drug may affect study within 7 day prior first dose study medication . Previously donate whole blood within 60 day component blood within 30 day prior first dose study medication . blood transfusion within 30 day prior first dose study medication . Subjects participation another clinical trial within 60 day prior study An impossible one participate clinical trial Principal investigator 's decision Normal Renal Function subject : Subjects history chronic disease acute illness within 28 day study medication administration Subjects history gastrointestinal disease effect study medication surgery ( except appendectomy , hernia surgery ) Current chronic history liver disease ascites hepatic encephalopathy Renally impaired subject : Type I diabetes , Diabetic ketoacidosis , diabetic coma history coma ( controllable Type II diabetes include possible ) Uncontrollable hypertension severe heart failure require treatment steroid immunosuppressive drug History renal transplant undergoing dialysis method except hemodialysis Needs treatment acute disease , uncontrolled disease diabetic complication Current chronic history liver disease ascites hepatic encephalopathy Subjects history chronic disease acute illness within 28 day study medication administration Subjects history gastrointestinal disease effect study medication surgery ( except appendectomy , hernia surgery )</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>